Why Is Pain & Liver Disease Focused DURECT Stock Plunging Today?
Portfolio Pulse from Vandana Singh
DURECT Corporation (NASDAQ:DRRX) released topline results from its AHFIRM Phase 2b study of larsucosterol in patients with severe alcohol-associated hepatitis (AH). The results did not achieve statistical significance for the primary endpoint of mortality or transplant at 90 days. However, both doses of larsucosterol showed a clinically meaningful trend in reduction of mortality at 90 days. DURECT plans to discuss the trial results and the Phase 3 registration trial design with the FDA in Q1 2024. DRRX shares are down 75.90% at $0.62.
November 08, 2023 | 4:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
DURECT's Phase 2b study results did not meet the primary endpoint, but showed a reduction in mortality. The company's shares are down 75.90%.
The company's stock price has plunged due to the disappointing results of the Phase 2b study. However, the reduction in mortality could be a positive sign for the future, which might mitigate the negative impact in the long term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100